{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:17:18Z","timestamp":1791883038795,"version":"4.3.4"},"reference-count":64,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In the present review, the authors report the published evidence on the use of functional imaging with FDG-PET\/CT in assessing the final response to treatment in Hodgkin lymphoma. Despite a very high overall Negative Predictive Value of post-chemotherapy PET on treatment outcome ranging from 94% to 86%, according to different treatment intensity, the Positive Predicting Value proved much lower (40\u201325%). In the present review the Authors discuss the role of PET to guide consolidation RT over a RM after different chemotherapy regimens, both in early and in advanced-stage disease. A particular emphasis is dedicated to the peculiar issue of the qualitative versus semi-quantitative methods for End-of Therapy PET scan interpretation. A short hint will be given on the role of FDG-PET to assess the treatment outcome after immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3390\/cancers13163952","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:35:32Z","timestamp":1628156132000},"page":"3952","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["FDG-PET\/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Andrea","family":"Gallamini","sequence":"first","affiliation":[{"name":"Research and Clinical Innovation Department, Antoine Lacassagne Cancer Centre, 06189 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-7425","authenticated-orcid":false,"given":"Micha\u0142","family":"Kurlapski","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplantation Department, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"Haematology and Bone Marrow Transplantation Department, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1988.6.6.931","article-title":"Residual mass in lymphoma may not be residual disease","volume":"6","author":"Canellos","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.1988.6.6.940","article-title":"The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin\u2019s disease","volume":"6","author":"Radford","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2001.03147.x","article-title":"Prognostic value of posi-tron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"115","author":"Naumann","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Engert, A., and Younes, A. (2015). Functional Imaging in Hodgkin lymphoma. Hodgkin lymphoma, Springer International Publishing.","DOI":"10.1007\/978-3-319-12505-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin\u2019s Disease and Non-Hodgkin\u2019s Lymphoma Has Higher Di-agnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","article-title":"The role of PET\/CT in the modern treatment of Hodgkin lymphoma","volume":"77","author":"Zaucha","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","first-page":"319","article-title":"Ueber den stoffwechsel der tumoren","volume":"152","author":"Warburg","year":"1924","journal-title":"Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: Pathology and biology","volume":"53","author":"Mathas","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","article-title":"Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes","volume":"111","author":"Ma","year":"2008","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3324\/haematol.2010.024885","article-title":"Positron emission tomography scanning: A new paradigm for the management of Hodgkin\u2019s lymphoma","volume":"95","author":"Gallamini","year":"2010","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2967\/jnumed.107.039867","article-title":"18F-FDG PET for Posttherapy Assessment of Hodgkin\u2019s Disease and Aggressive Non-Hodgkin\u2019s Lymphoma: A Systematic Review","volume":"49","author":"Terasawa","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin\u2019s Lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/10428190701422414","article-title":"Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria","volume":"48","author":"Brepoels","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evalua-tion, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","article-title":"Advanced Stage Classical Hodgkin lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation","volume":"126","author":"Savage","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiationversusobservation in bulky Hodgkin\u2019s lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early Chemotherapy Intensification with Escalated BEACOPP in Patients with Advanced-Stage Hodgkin lymphoma with a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin lymphoma with Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL\/FIL HD0607 Trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Ad-vanced Hodgkin\u2019s Disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight Cycles of Escalated-Dose BEACOPP Compared with Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP with or without Radiotherapy in Patients with Advanced-Stage Hodgkin\u2019s Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group","volume":"29","author":"Borchmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thorac-ic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch","year":"2001","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"ref_30","unstructured":"Kobe, C. Recommendation of GHSG for Consolidative Radiotherapy of Residual Mass in Patients with Advanced Hodgkin lymphoma after Effective BEACOPPesc Treatment. Personal communication."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2020.03.008","article-title":"2-deoxy-2[F-18] fluoro-d-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma","volume":"132","author":"Picardi","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_33","first-page":"70","article-title":"Quantitative and qualitative evaluation of the interim PET\/CT in lymphoma treatment in the prediction of complete metabolic response","volume":"32","author":"Woll","year":"2013","journal-title":"Rev. Esp. Med. Nucl. Imagen. Mol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s12149-017-1196-x","article-title":"Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET\/CT according to \u0394SUV(max), Deauville 5-point scale and IHP criteria","volume":"31","author":"Isik","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11899-011-0090-1","article-title":"Primary Mediastinal Large B-Cell Lymphoma, Classic Hodgkin lymphoma Presenting in the Mediastinum, and Mediastinal Gray Zone Lymphoma: What is the Oncologist to do?","volume":"6","author":"Grant","year":"2011","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/1097-0142(196910)24:4<709::AID-CNCR2820240408>3.0.CO;2-E","article-title":"The value of laparotomy and splenectomy in the staging of Hodgkin\u2019s disease","volume":"24","author":"Glatstein","year":"1969","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Durmo, R., Cottereau, A.S., Rebaud, L., Nioche, C., Ruffini, A., Fioroni, F., Meignan, M., Buvat, I., Merli, F., and Versari, A. (2021). Prognostic role of lesion dissemination feature (dmax) calculated on baseline pet\/ct in hodgkin lymphoma. Hematol. Oncol., 39.","DOI":"10.1002\/hon.20_2879"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Trichelair, P. (2021). How machine learning can enhance clinical development. Hematol. Oncol., 39.","DOI":"10.1002\/hon.10_2879"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00259-019-04310-x","article-title":"Unconventional immune-related phenomena observed using 18F-FDG PET\/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies","volume":"46","author":"Dercle","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): A multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1148\/radiol.2020192056","article-title":"Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin lymphoma","volume":"295","author":"Mokrane","year":"2020","journal-title":"Radiology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1\/2 Study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Alizadeh, A. (2021). The architecture of liquid biopsy research for lymphoma monitoring. Hematol. Oncol., 39.","DOI":"10.1002\/hon.2_2879"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000001344","article-title":"Comparison of PET\/MRI with PET\/CT in the Evaluation of Disease Status in Lymphoma","volume":"42","author":"Afaq","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00261-016-0638-6","article-title":"Hybrid FDG-PET\/MR compared to FDG-PET\/CT in adult lymphoma patients","volume":"41","author":"Atkinson","year":"2016","journal-title":"Abdom. Radiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1593\/neo.81328","article-title":"Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations","volume":"11","author":"Padhani","year":"2009","journal-title":"Neoplasia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.ejrad.2014.05.027","article-title":"Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity\u2014A preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging","volume":"83","author":"Horger","year":"2014","journal-title":"Eur. J. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1148\/radiol.2492071681","article-title":"Variability in Absolute Apparent Diffusion Coefficient Values across Different Platforms May Be Substantial: A Multivendor, Multi-institutional Comparison Study","volume":"249","author":"Sasaki","year":"2008","journal-title":"Radiology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Brancato, V., Aiello, M., Della Pepa, R., Basso, L., Garbino, N., Nicolai, E., Picardi, M., Salvatore, M., and Cavaliere, C. (2020). Automatic Prediction and Assessment of Treatment Response in Patients with Hodgkin\u2019s Lymphoma Using a Whole-Body DW-MRI Based Approach. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090702"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MNM.0000000000000697","article-title":"Usual and unusual pitfalls of 18F-FDG-PET\/CT in lymphoma after treatment","volume":"38","author":"Dubreuil","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2967\/jnumed.108.058586","article-title":"Physiologic Thymic Uptake of 18F-FDG in Children and Young Adults: A PET\/CT Evaluation of Incidence, Patterns, and Relationship to Treatment","volume":"50","author":"Jerushalmi","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/annonc\/mdw193","article-title":"Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: Which is more appropriate terminology?","volume":"27","author":"Paydas","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Pradelli","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.10798","article-title":"Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma","volume":"92","author":"Zinzani","year":"2007","journal-title":"Haematologica"},{"key":"ref_62","first-page":"1412","article-title":"Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes","volume":"42","author":"Zhuang","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_63","first-page":"176","article-title":"Dual-point FDG-PET\/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment","volume":"9","author":"Borra","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lym-phoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/3952\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:56Z","timestamp":1760164856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/3952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":64,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13163952"],"URL":"https:\/\/doi.org\/10.3390\/cancers13163952","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}